MCID: SYS001
MIFTS: 86

Systemic Lupus Erythematosus

Categories: Genetic diseases, Rare diseases, Skin diseases, Bone diseases, Nephrological diseases, Immune diseases

Aliases & Classifications for Systemic Lupus Erythematosus

MalaCards integrated aliases for Systemic Lupus Erythematosus:

Name: Systemic Lupus Erythematosus 53 37 12 72 24 50 71 36 28 3 14
Lupus Nephritis 53 12 49 36 51 41 14 69
Lupus Erythematosus, Systemic 12 41 69
Sle 53 24 71
Disseminated Lupus Erythematosus 12 24
Libman-Sacks Disease 24 69
Systemic Lupus Erythematosus, Susceptibility to 53
Systemic Lupus Erythematosus Susceptibility to 53
Sle - Lupus Erythematosus, Systemic 12
Lupus Nephritis, Susceptibility to 53
Lupus Erythematosus Systemic 51
Lupus Erythematosus, Discoid 69
Lupus Erythematosus 69
Lupus Vulgaris 69
Le Syndrome 24
Lupus 24

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant

Miscellaneous:
complement deficiency (e.g. c2 and c4 null alleles) are susceptible to developing sle
association between hla class ii alleles and presence of autoantibodies
onset between ages 16-55
female to male ratio 8-13:1


HPO:

31
systemic lupus erythematosus:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Systemic Lupus Erythematosus

NINDS : 50 Lupus (also called systemic lupus erythematosus) is a disorder of the immune system. Normally, the immune system protects the body against invading infections and cancers. In lupus, the immune system is over-active and produces increased amounts of abnormal antibodies that attack the body's tissues and organs. Lupus can affect many parts of the body, including the joints, skin, kidneys, lungs, heart, nervous system, and blood vessels. The signs and symptoms of lupus differ from person to person; the disease can range from mild to life threatening. Initial symptoms of lupus may begin with a fever, vascular headaches, epilepsy, or psychoses. A striking feature of lupus is a butterfly shaped rash over the cheeks. In addition to headache, lupus can cause other neurological disorders, such as mild cognitive dysfunction, organic brain syndrome, peripheral neuropathies, sensory neuropathy, psychological problems (including personality changes, paranoia, mania, and schizophrenia), seizures, transverse myelitis, and paralysis and stroke.

MalaCards based summary : Systemic Lupus Erythematosus, also known as lupus nephritis, is related to systemic lupus erythematosus 16 and pediatric systemic lupus erythematosus, and has symptoms including seizures, arthritis and hemolytic anemia. An important gene associated with Systemic Lupus Erythematosus is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways/superpathways are Systemic lupus erythematosus and Innate Immune System. The drugs Simvastatin and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, t cells and skin, and related phenotypes are hematopoietic system and immune system

OMIM : 53 Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies against nuclear, cytoplasmic, and cell surface molecules that transcend organ-specific boundaries. Tissue deposition of antibodies or immune complexes induces inflammation and subsequent injury of multiple organs and finally results in clinical manifestations of SLE, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures, and arthritis. Evidence strongly suggests the involvement of genetic components in SLE susceptibility (summary by Oishi et al., 2008). (152700)

UniProtKB/Swiss-Prot : 71 Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

NIH Rare Diseases : 49 Lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematous (SLE), commonly known as lupus. The symptoms of lupus nephritis include blood in the urine, a foamy appearance to the urine, high blood pressure, and swelling in any part of the body. This condition typically occurs in people aged 20 to 40 years. Treatment may involve medications to suppress the immune system, dialysis, or a kidney transplant. Visit our Web page on lupus for more information and resources. Last updated: 11/24/2010

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

Genetics Home Reference : 24 Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs.

Disease Ontology : 12 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart.

Wikipedia : 72 Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the... more...

Related Diseases for Systemic Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 896)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 35.4 C4A DNASE1
2 pediatric systemic lupus erythematosus 35.0 C4A C4B PTPN22
3 systemic lupus erythematosus 1 35.0 ENG TLR5 TREX1
4 lupus erythematosus 35.0 BANK1 C4A C4B CTLA4 DNASE1 ENG
5 vitiligo-associated multiple autoimmune disease susceptibility 1 34.5 C4B CTLA4 PTPN22
6 neonatal lupus erythematosus 34.3 C4A TRIM21
7 autoimmune disease 31.9 CTLA4 FCGR2A FCGR2B FCGR3A PDCD1 PTPN22
8 hypersensitivity reaction type iii disease 30.5 C4A C4B
9 systemic lupus erythematosus 2 12.6
10 systemic lupus erythematosus 9 12.5
11 systemic lupus erythematosus 10 12.5
12 systemic lupus erythematosus 6 12.5
13 systemic lupus erythematosus 11 12.5
14 systemic lupus erythematosus with hemolytic anemia 1 12.4
15 systemic lupus erythematosus 3 12.4
16 systemic lupus erythematosus with nephritis 1 12.4
17 systemic lupus erythematosus with nephritis 2 12.4
18 systemic lupus erythematosus with nephritis 3 12.4
19 systemic lupus erythematosus 4 12.4
20 systemic lupus erythematosus 5 12.4
21 systemic lupus erythematosus 12 12.4
22 neonatal systemic lupus erythematosus 12.3
23 systemic lupus erythematosus 15 12.2
24 systemic lupus erythematosus 7 12.2
25 systemic lupus erythematosus 8 12.2
26 systemic lupus erythematosus 13 12.2
27 systemic lupus erythematosus 14 12.2
28 c1q deficiency 11.7
29 mixed connective tissue disease 11.7
30 drug-induced lupus erythematosus 11.4
31 hypogonadotropic hypogonadism 11.4
32 pure red-cell aplasia 11.4
33 cutaneous lupus erythematosus 11.4
34 sjogren syndrome 11.4
35 macrophage activation syndrome 11.4
36 epidermolysis bullosa acquisita 11.4
37 renal tubular acidosis, distal 11.4
38 undifferentiated connective tissue disease 11.4
39 sneddon syndrome 11.4
40 complement component 3 deficiency, autosomal recessive 11.4
41 complement component c1s deficiency 11.4
42 rapidly progressive glomerulonephritis 11.4
43 lupus erythematosus tumidus 11.4
44 spondyloenchondrodysplasia 11.4
45 mesangial proliferative glomerulonephritis 11.2
46 complement component 2 deficiency 11.1
47 pseudo-torch syndrome 1 11.1
48 glomerulopathy with fibronectin deposits 2 11.1
49 chilblain lupus 1 11.1
50 autoimmune disease 6 11.1

Comorbidity relations with Systemic Lupus Erythematosus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Neutropenia
Osteoporosis Postinflammatory Pulmonary Fibrosis
Raynaud Disease Rheumatoid Arthritis
Sjogren Syndrome Systemic Scleroderma

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus:



Diseases related to Systemic Lupus Erythematosus

Symptoms & Phenotypes for Systemic Lupus Erythematosus

Symptoms via clinical synopsis from OMIM:

53
Neurologic Central Nervous System:
seizures
psychosis

Hematology:
hemolytic anemia
thrombocytopenia
leukopenia

Respiratory Lung:
pleuritis

Genitourinary Kidneys:
nephritis

Laboratory Abnormalities:
antiphospholipid antibody
anti dsdna antibody
serum antinuclear antibody

Skeletal Limbs:
arthritis

Cardiovascular Heart:
pericarditis

Immunology:
systemic lupus erythematosus

Skin Nails Hair Skin:
photosensitivity
erythematous malar rash
discoid rash


Clinical features from OMIM:

152700

Human phenotypes related to Systemic Lupus Erythematosus:

31 (show all 13)
# Description HPO Frequency HPO Source Accession
1 seizures 31 HP:0001250
2 arthritis 31 HP:0001369
3 hemolytic anemia 31 HP:0001878
4 thrombocytopenia 31 HP:0001873
5 psychosis 31 HP:0000709
6 pericarditis 31 HP:0001701
7 cutaneous photosensitivity 31 HP:0000992
8 leukopenia 31 HP:0001882
9 pleuritis 31 HP:0002102
10 systemic lupus erythematosus 31 HP:0002725
11 antinuclear antibody positivity 31 HP:0003493
12 nephritis 31 HP:0000123
13 antiphospholipid antibody positivity 31 HP:0003613

UMLS symptoms related to Systemic Lupus Erythematosus:


seizures, pruritus, heliotrope rash, lupus-like rash, exanthema

MGI Mouse Phenotypes related to Systemic Lupus Erythematosus:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 CTLA4 DNASE1 ENG FCGR2A FCGR2B PDCD1
2 immune system MP:0005387 10 BANK1 C4B CTLA4 DNASE1 FCGR2A FCGR2B
3 digestive/alimentary MP:0005381 9.91 C4B CTLA4 ENG FCGR2B PTPN22 TLR5
4 liver/biliary system MP:0005370 9.7 C4B CTLA4 FCGR2B PDCD1 PTPN22 TLR5
5 renal/urinary system MP:0005367 9.5 DNASE1 FCGR2B PDCD1 PTPN22 TREX1 TRIM21
6 respiratory system MP:0005388 9.17 CTLA4 ENG FCGR2B PDCD1 PTPN22 TLR5

Drugs & Therapeutics for Systemic Lupus Erythematosus

Drugs for Systemic Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Everolimus Approved Phase 4,Phase 2 159351-69-6 6442177
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
9
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 6436030 5284616
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
12
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
13
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
14
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
15
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-78-2 2244
16
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
17
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
18
Lenalidomide Approved Phase 4 191732-72-6 216326
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
21
Thioguanine Approved Phase 4 154-42-7 2723601
22
Metformin Approved Phase 4 657-24-9 4091 14219
23
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
24
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
25
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
28
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-14-6 5280793
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 1406-16-2
30 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2
37 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
40 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
41 Antifungal Agents Phase 4,Phase 2,Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
45 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
46 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
50 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 548)

# Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
5 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
6 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
7 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
8 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
9 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
10 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
11 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
12 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
13 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
14 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
15 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
16 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
19 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
20 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
21 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
22 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
23 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
24 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
25 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
26 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
27 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4 RAYOS;Prednisone
28 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
29 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
30 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
31 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4 Azathioprine
32 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
33 The Effect of Metformin on Reducing Lupus Flares Active, not recruiting NCT02741960 Phase 4 metformin;placebo
34 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
35 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
36 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
37 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Not yet recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
38 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Not yet recruiting NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
39 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
40 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
41 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
42 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
43 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
44 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
45 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
46 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)
47 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy
48 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
49 GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Completed NCT00082511 Phase 3 Prasterone (GL701)
50 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed NCT00410384 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg

Search NIH Clinical Center for Systemic Lupus Erythematosus

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Lupus Erythematosus cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lupus nephritis

Genetic Tests for Systemic Lupus Erythematosus

Genetic tests related to Systemic Lupus Erythematosus:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 28 BANK1 CTLA4 DNASE1 FCGR2A FCGR2B PTPN22 TREX1

Anatomical Context for Systemic Lupus Erythematosus

MalaCards organs/tissues related to Systemic Lupus Erythematosus:

38
T Cells, Skin, Kidney, B Cells, Heart, Endothelial, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Systemic Lupus Erythematosus:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Systemic Lupus Erythematosus

Articles related to Systemic Lupus Erythematosus:

(show top 50) (show all 5330)
# Title Authors Year
1
The interplay between tuberculosis and systemic lupus erythematosus. ( 29438163 )
2018
2
Clinical Factors Associated with Brain Volume Reduction in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations. ( 29449817 )
2018
3
Synchronous presentation of systemic lupus erythematosus and oral reticular lichen planus. ( 29387764 )
2018
4
Anti-tubulin-I+-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations. ( 29427009 )
2018
5
Prevalence and factors associated with fatigue in female patients with systemic lupus erythematosus. ( 29439873 )
2018
6
DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. ( 29437559 )
2018
7
Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? ( 29119304 )
2018
8
CCR6<sup>+</sup>Th cell distribution differentiates systemic lupus erythematosus patients based on anti-dsDNA antibody status. ( 29441231 )
2018
9
Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud's arthropathy. ( 29338586 )
2018
10
Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( 29451069 )
2018
11
Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy. ( 29449503 )
2018
12
Combination of ofatumumab and fresh frozen plasma in hypocomplementemic systemic lupus erythematosus: a case report. ( 29439647 )
2018
13
Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. ( 29294596 )
2018
14
Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). ( 29444908 )
2018
15
Pregnancy complicated by systemic lupus erythematosus and its outcome over 10 years. ( 29433371 )
2018
16
Latent systemic lupus erythematosus presenting with hypokalaemic quadriparesis and central pontine myelinolysis. ( 29429118 )
2018
17
Association of interleukin-10 gene single nucleotide polymorphisms with susceptibility to systemic lupus erythematosus in a Chinese population. ( 29199038 )
2018
18
An interesting case of systemic lupus erythematosus in a patient with Moebius syndrome. ( 29356035 )
2018
19
DNA induction of MDM2 promotes proliferation of human renal mesangial cells and alters peripheral B cells subsets in pediatric systemic lupus erythematosus. ( 29324237 )
2018
20
Olfactory function in systemic lupus erythematosus and systemic sclerosis. A longitudinal study and review of the literature. ( 29444467 )
2018
21
Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus. ( 29434811 )
2018
22
Systemic lupus erythematosus with C1q deficiency: treatment with fresh frozen plasma. ( 29113537 )
2018
23
Features, Treatment and Outcomes of Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus. ( 29342508 )
2018
24
Cardiac tamponade in systemic lupus erythematosus. ( 29048543 )
2018
25
<i>Candida albicans</i> Pyomyositis in a Patient with Systemic Lupus Erythematosus. ( 29419450 )
2018
26
Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. ( 29431056 )
2018
27
Correction:<i>Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016</i>. ( 29440018 )
2018
28
Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus. ( 29451066 )
2018
29
The influence of functional polymorphic positions of HLA-DRI^1 molecules on risk for South Indian systemic lupus erythematosus patients. ( 29439646 )
2018
30
Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus. ( 28237708 )
2017
31
Association Between TNF-I+ Promoter -308 A/G Polymorphism and Systemic Lupus Erythematosus Susceptibility: A Case-Control Study and Meta-Analysis. ( 27943420 )
2017
32
Association Between Major Histocompatibility Complex Class I Chain-Related Gene Polymorphisms and Susceptibility of Systemic Lupus Erythematosus. ( 29078849 )
2017
33
Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity. ( 29080553 )
2017
34
Gestational gigantomastia in systemic lupus erythematosus. ( 29272260 )
2017
35
TIGIT signalling pathway negatively regulates CD4(+) T-cell responses in systemic lupus erythematosus. ( 28108989 )
2017
36
Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study. ( 28091805 )
2017
37
What Can We Do When All Collapses? Fatal Outcome of Collapsing Glomerulopathy and Systemic Lupus Erythematosus With Diffuse Alveolar Hemorrhage: Case Report. ( 28457424 )
2017
38
Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus. ( 28065614 )
2017
39
Novel CMR techniques enable detection of even mild autoimmune myocarditis in a patient with systemic lupus erythematosus. ( 28321496 )
2017
40
Systemic lupus erythematosus in the light of the regulatory effects of galectin-1 on T-cell function. ( 28100106 )
2017
41
Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease. ( 28530467 )
2017
42
Hashimoto thyroiditis, anti-thyroid antibodies and systemic lupus erythematosus. ( 28544477 )
2017
43
Acute acalculous cholecystitis in patients with systemic lupus erythematosus: A unique form of disease flare. ( 28355987 )
2017
44
Association of IRF5 polymorphisms with increased risk for systemic lupus erythematosus in population of Crete, a southern-eastern European Greek island. ( 28185859 )
2017
45
Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. ( 28085900 )
2017
46
Serum interleukin-17 in Egyptian children with systemic lupus erythematosus: is it related to pulmonary affection? ( 27587461 )
2017
47
Decreased mRNA expression levels of DNA methyltransferases type 1 and 3A in systemic lupus erythematosus. ( 28349196 )
2017
48
Associations between PTPN22 and TLR9 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis. ( 28528372 )
2017
49
Spatial Working Memory Impairment in Patients with Non-neuropsychiatric Systemic Lupus Erythematosus: A Blood-oxygen-level Dependent Functional Magnetic Resonance Imaging Study. ( 28089970 )
2017
50
ANCA-Positive pauci-immune crescentic glomerulonephritis in a patient with systemic lupus erythematosus. ( 29319773 )
2017

Variations for Systemic Lupus Erythematosus

UniProtKB/Swiss-Prot genetic disease variations for Systemic Lupus Erythematosus:

71
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601
2 TREX1 p.Arg114His VAR_028319 rs72556554
3 TREX1 p.Ala158Val VAR_037949 rs762011967
4 TREX1 p.Gly227Ser VAR_037950 rs113107733
5 TREX1 p.Arg240Ser VAR_037951 rs72556555
6 TREX1 p.Ala247Pro VAR_037952 rs112741962
7 TREX1 p.Pro290Leu VAR_037954 rs148833270
8 TREX1 p.Tyr305Cys VAR_037955 rs370504038
9 TREX1 p.Gly306Ala VAR_037956 rs780022923
10 TREX1 p.Asp200His VAR_070901

ClinVar genetic disease variations for Systemic Lupus Erythematosus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395
2 ENG NM_000118.3(ENG): c.816+6T> C single nucleotide variant Pathogenic rs759191907 GRCh38 Chromosome 9, 127825225: 127825225

Copy number variations for Systemic Lupus Erythematosus from CNVD:

7 (show all 43)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14694 1 110000000 163800000 Gain or loss FCGR3B Systemic lupus erythematosus
2 21050 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
3 21051 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
4 21053 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
5 21628 1 159859611 159867782 Copy number FCGR3B Systemic lupus erythematosus
6 21630 1 159859611 159867782 Low copy number FCGR3B Systemic lupus erythematosus
7 21794 1 161592989 161601158 Copy number FCGR3B Systemic lupus erythematosus
8 21797 1 161592989 161601158 Deletion FCGR3B Systemic lupus erythematosus
9 107133 17 1225928 31649829 Copy number CCL3L3 Systemic lupus erythematosus
10 107143 17 1225928 31649843 Copy number CCL3L1 Systemic lupus erythematosus
11 107163 17 1242109 31665953 Copy number CCL4L2 Systemic lupus erythematosus
12 110232 17 31562580 31665959 Copy number CCL4L1 Systemic lupus erythematosus
13 110282 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
14 110283 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
15 110288 17 31800000 38100000 Copy number CCL4L1 Systemic lupus erythematosus
16 112168 17 38100000 38400000 Copy number CCL3L1 Systemic lupus erythematosus
17 113342 17 43165608 43178484 Amplification T-bet Systemic lupus erythematosus
18 162470 22 21800000 24300000 Gain or loss GSTT1 Systemic lupus erythematosus
19 186012 4 2713184 2727859 Deletion TNIP2 Systemic lupus erythematosus
20 196060 5 158674368 158690059 Amplification IL-12B Systemic lupus erythematosus
21 204042 6 105500000 114600000 Copy number C4A Systemic lupus erythematosus
22 204043 6 105500000 114600000 Copy number C4B Systemic lupus erythematosus
23 207132 6 15200000 46200000 Copy number Systemic lupus erythematosus
24 209409 6 2614953 31491069 Copy number MICA Systemic lupus erythematosus
25 210235 6 29900000 36800000 Low copy numbers C4 Systemic lupus erythematosus
26 210494 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
27 210495 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
28 210499 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
29 210506 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
30 210507 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
31 210512 6 30400000 36600000 Gain C4A Systemic lupus erythematosus
32 210513 6 30400000 36600000 Gain C4B Systemic lupus erythematosus
33 211033 6 31949833 32003194 Copy number C4A Systemic lupus erythematosus
34 211045 6 3197570 32111174 Copy number C4A Systemic lupus erythematosus
35 211049 6 3197570 32111174 Duplication C4 Systemic lupus erythematosus
36 211054 6 31982571 32003194 Copy number C4B Systemic lupus erythematosus
37 211360 6 32593131 32665540 Copy number HLA-DRB5 Systemic lupus erythematosus
38 212285 6 3674895 32665540 Copy number HLA-DRB1 Systemic lupus erythematosus
39 212431 6 3795995 32719407 Copy number HLA-DQA1 Systemic lupus erythematosus
40 212452 6 3813334 32742444 Copy number HLA-DQB1 Systemic lupus erythematosus
41 212671 6 40500000 46200000 Copy number Systemic lupus erythematosus
42 212678 6 40500000 93100000 Copy number Systemic lupus erythematosus
43 243031 8 7752198 7754236 Copy number DEFB4 Systemic lupus erythematosus

Expression for Systemic Lupus Erythematosus

LifeMap Discovery
Genes differentially expressed in tissues of Systemic Lupus Erythematosus patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 5.47 0.000
2 OTOF otoferlin Blood + 5.25 0.000
3 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood - 4.40 0.000
4 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Blood + 4.22 0.000
5 LINC00661 long intergenic non-protein coding RNA 661 Blood + 4.15 0.000
6 SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin Blood + 4.12 0.000
7 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood - 3.96 0.000
8 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.81 0.000
9 IFI44L interferon-induced protein 44-like Blood + 3.58 0.000
10 USP41 ubiquitin specific peptidase 41 Blood + 3.40 0.000
11 HESX1 HESX homeobox 1 Blood + 3.22 0.000
12 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Blood + 3.08 0.000
Search GEO for disease gene expression data for Systemic Lupus Erythematosus.

Pathways for Systemic Lupus Erythematosus

Pathways related to Systemic Lupus Erythematosus according to KEGG:

36
# Name Kegg Source Accession
1 Systemic lupus erythematosus hsa05322

Pathways related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 C4A C4B CTLA4 FCGR2A FCGR2B FCGR3A
2 11.6 FCGR2A FCGR2B FCGR3A
3 11.29 FCGR2A FCGR2B FCGR3A
4 11.1 C4A C4B FCGR2A FCGR2B FCGR3A
5 10.92 CTLA4 FCGR2A FCGR2B FCGR3A PDCD1 TLR5

GO Terms for Systemic Lupus Erythematosus

Cellular components related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 CTLA4 ENG FCGR2B FCGR3A PDCD1

Biological processes related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.65 C4A C4B CTLA4 PTPN22 TLR5
2 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0038096 9.63 FCGR2A FCGR2B FCGR3A
3 regulation of type I interferon production GO:0032479 9.43 TREX1 TRIM21
4 negative regulation of B cell proliferation GO:0030889 9.4 CTLA4 FCGR2B
5 regulation of innate immune response GO:0045088 9.37 FCGR2B PTPN22
6 negative regulation of immune response GO:0050777 9.32 CTLA4 FCGR2B
7 negative regulation of B cell activation GO:0050869 9.16 BANK1 FCGR2B
8 negative regulation of interleukin-6 secretion GO:1900165 8.96 BANK1 PTPN22
9 positive regulation of apoptotic cell clearance GO:2000427 8.62 C4A C4B

Molecular functions related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase binding GO:1990782 8.96 BANK1 PTPN22
2 IgG binding GO:0019864 8.8 FCGR2A FCGR2B FCGR3A

Sources for Systemic Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....